RxDoctor Payments Data

Hieu Huynh, MD

Cardiovascular Disease · Sacramento, CANPI 1003938192

Payments from drug & device makers

$5,201in general payments, 2019–2025

Across 37 payments — averaging $140.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Biotronik Inc.$4K
  • Medtronic$633
  • Abbott$185
  • Boston Scientific$82
  • Regeneron Healthcare Solutions, Inc.$27
  • Pfizer$23

What the payments were for

  • Travel & lodging$3,95576%
  • Food & beverage$1,15222%
  • Education$942%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,201 in reported general payments places this provider in the 60th percentile of 2,184 cardiovascular disease providers in California.

See all cardiovascular disease providers in California

Medicare billing

Part B allowed, 2024
$283,717
Medicare patients
1,244
Services billed
3,631

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VyndamaxTafamidis25$550,295
EliquisApixaban354$393,237
Repatha SureclickEvolocumab141$117,217
EntrestoSacubitril/Valsartan54$79,488
MultaqDronedarone Hcl45$49,833
XareltoRivaroxaban29$34,607
FarxigaDapagliflozin Propanediol34$29,430
Ezetimibe323$13,127
VascepaIcosapent Ethyl26$9,195
Metoprolol Succinate420$7,154
Nebivolol Hcl87$5,844
Atorvastatin Calcium489$4,937
Ranolazine ErRanolazine30$4,609
Amlodipine Besylate343$2,750
Telmisartan86$2,692

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerVyndamax, Eliquis$23$943,532379 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 2,184 cardiovascular disease providers in California.

Other cardiovascular disease in Sacramento

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →